Foundation Fighting Blindness and RetroSense Therapeutics Make Progress Toward First-Ever Clinical Trial for Optogenetic Gene Therapy Treatment

FDA Meeting Clarifies Path to the Clinic for Innovative Gene Therapy to Restore VisionAfter a productive meeting this week with the U.S. Food and Drug Administration (FDA), the Foundation Fighting Blindness  acknowledges a clearer path to the clinic for an innovative gene therapy developed by RetroSense Therapeutics (file:///C:/Users/agebhardt/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.Outlook/2PYUVSXP/RetroSense%20Therapeutics) to restore vision in people with a wide range of advanced retinal degenerative diseases. With discussions